FT Options Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$3.53M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$2.94M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$2.18M |
| 4 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$1.54M |
| 5 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$1.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
General Mills
GIS
|
+$2.52M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$2.31M |
| 3 |
Amgen
AMGN
|
+$2.08M |
| 4 |
Abbott
ABT
|
+$1.72M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$1.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.81% |
| 2 | Consumer Discretionary | 7.1% |
| 3 | Consumer Staples | 6.25% |
| 4 | Communication Services | 0.99% |
| 5 | Materials | 0.21% |
No holdings matched the selected filter criteria.
Similar funds
FT Options's Q3 2017 Portfolio in Review
As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.
- FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
- FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
- FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
- FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
- FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
- FT Options opened 108 new positions and closed 72 in Q3 2017.
- FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.
Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.